My Cart (0 )
-
Previous
Rocaglamide Liposomes, Formulation KHE9A
$1,295.00 – $3,295.00
-
Next
AZD1208 Liposomes, Formulation RB4T4
$1,295.00 – $1,995.00
Gilteritinib (ASP2215) Liposomes
$995.00 – $4,095.00
Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only.
We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.
Available Options:
Specifications
Product Data:
Figure 1 (Thumbnail). Solubilization of Gilteritinib (ASP2215) by liposomes. Gilteritinib is shown under magnification in free or liposomal forms at 2.5 mg/mL. Left: Gilteritinib (ASP2215) is insoluble in aqueous media. Gilteritinib (ASP2215) was dissolved in DMSO and diluted in 154 mM NaCl, pH 5.5 to examine aqueous solubility. Right: Matched concentration of Gilteritinib (ASP2215) is shown in liposomal form, in the same bulk solution.
Figure 2. DLS analysis of Gilteritinib (ASP2215) Liposomes, Formulation MCR5N.2 (batch 52632). The average size and PDI of triplicate measurements are annotated on the representative snapshot from DLS data acquisition screen. The data are representative of a typical batch.
Details
|
|
|
|
DLL-0021 |
|
|
PEGylated liposomes loaded with Gilteritinib (ASP2215) |
|
| Formulation No. | MCR5N.2 |
| Lipid Composition | HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3, mol/mol) |
| Concentration Total Lipid | 26.4 mM |
| Concentration Gilteritinib | 2.5 mg/mL |
| Hydration Solution | 250 mM ammonium sulfate, pH 5.5 |
| External Solution | DPBS (1X), pH 7.4 |
| Liposome Avg. Size | 70-120 nm |
Bioactive Compound Details
|
|
| Encapsulated Compound | Gilteritinib |
| Alias(es) | ASP2215; HY-12432; S7754 |
| CAS No. | 1254053-43-4 |
| Target(s) | FLT3/AXL |
| Signaling Pathway | FLT3 pathway (activity against FLT3-ITD and FLT-TKD mutational subtypes); AXL pathway |
Custom Orders
We synthesize custom liposomes like this. If you would like to modify this product with fluorescent dyes (DiR, DiD, DiO, DiI, etc.), targeting ligands (cRGD, folate, etc.), or something else, please request a custom formulation.
Quick Links:
Liposome Formulation Development
Additional Information
Additional Information
| Liquid, suspension | |
| 2 °C to 8 °C (do not freeze), stored under nitrogen | |
| Shelf Life* | At least 3 months |
| Applications | |
| Background | |
| References |
*Product is too new for long-term stability data. This section will be updated regularly as new data becomes available.